Meenhard Herlyn

Affiliations: 
Bioengineering University of Pennsylvania, Philadelphia, PA, United States 
Area:
Biomedical Engineering, Oncology, Cell Biology
Google:
"Meenhard Herlyn"

Children

Sign in to add trainee
Chelsea C. Pinnix grad student 2006 Penn
Gao Zhang grad student 2012 Penn
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Webster MR, Fane ME, Alicea GM, et al. (2019) Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in Melanoma. Molecular Cell
Griss J, Bauer W, Wagner C, et al. (2019) B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. Nature Communications. 10: 4186
Buj R, Chen CW, Dahl ES, et al. (2019) Suppression of p16 Induces mTORC1-Mediated Nucleotide Metabolic Reprogramming. Cell Reports. 28: 1971-1980.e8
Aloia A, Müllhaupt D, Chabbert CD, et al. (2019) A fatty acid oxidation-dependent metabolic shift regulates the adaptation of -mutated melanoma to MAPK inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research
Liu S, Zhang G, Guo J, et al. (2019) Author Correction: Loss of Phd2 cooperates with BRAF to drive melanomagenesis. Nature Communications. 10: 1211
Sahu AD, S Lee J, Wang Z, et al. (2019) Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy. Molecular Systems Biology. 15: e8323
Atay C, Kwak T, Lavilla-Alonso S, et al. (2019) BRAF targeting sensitizes resistant melanoma to cytotoxic T cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research
Liu S, Zhang G, Guo J, et al. (2018) Loss of Phd2 cooperates with BRAF to drive melanomagenesis. Nature Communications. 9: 5426
Ojha R, Leli NM, Onorati A, et al. (2018) ER translocation of the MAPK pathway drives therapy resistance in BRAF mutant melanoma. Cancer Discovery
Lu H, Liu S, Zhang G, et al. (2018) Author Correction: PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature
See more...